Alpha

Archives
Subscribe
May 8, 2026

Alpha Signal Monitor - Daily Market Briefing | May 08, 2026

Daily Market Research Report

May 08, 2026

Alpha Signal Monitor

Welcome to your daily pre-market briefing. This report provides key insights on market opportunities and analyst perspectives to help identify potential alpha signals.

Today's Coverage: - Gold ETF Outlook: Institutional perspectives on gold-backed ETFs - Stock Ratings: Latest analyst ratings and target prices for our watchlist - IPO Calendar: Upcoming initial public offerings and market debuts

Watchlist Stocks: AAPL, MSFT, GOOGL, AMZN, NVDA, META, TSLA, AVGO, TSM


This report is generated using advanced AI research capabilities with real-time market data access.


Major banks’ latest views on gold ETFs (GLD, IAU, BAR) — as of May 8, 2026

Trading Idea: Buy Rationale (TL;DR): Broadly bullish institutional targets for late‑2026 ($5,200–$6,300/oz) still sit above spot after the spring pullback, with central‑bank demand and policy uncertainty providing support; physically backed ETFs (GLD, IAU, BAR) are direct ways to express the view. (investing.com)

Gold set fresh records above $5,500/oz in late January 2026, then corrected into March/April amid USD strength, higher real yields and investor de‑risking, but banks still cite strong central‑bank buying and prospective Fed easing as medium‑term tailwinds. (ubs.com)

Key Drivers - Central‑bank purchases remain elevated; JPM forecasts ~800 tonnes of buying in 2026, reinforcing structural demand. (investing.com) - Policy path and real yields: expectations for easier policy into late‑2026 and potential declines in real yields are supportive. (morganstanley.com) - Persistent macro/geopolitical risk supports hedging demand (Middle East tensions, trade frictions). (ubs.com) - ETF and private‑sector inflows can amplify moves, per bank commentaries. (bloomberg.com) - USD path and fiscal dynamics (large deficits) add to diversification demand. (hsbc.com.tw)

Institution Stance Price View Key Evidence Last Update Source
Goldman Sachs Bullish $5,400/oz by Dec 2026 GS reiterated a medium‑term bullish view despite the selloff, citing continued central‑bank purchases and scope for renewed gains into end‑2026. 2026-03-31 Bloomberg: Goldman still sees gold at $5,400 by year‑end (Mar 31, 2026). (bloomberg.com)
Morgan Stanley Constructive (less bullish than peers) ~$5,200/oz in H2 2026 MS Research expects prices could rise to ~$5,200 in the second half, noting near‑term realities (higher yields/stronger USD) temper upside vs earlier bull case. 2026-05-05 Morgan Stanley Insights: Gold’s Safe‑Haven Status Faces a Reality Check (May 5, 2026). (morganstanley.com)
JP Morgan Bullish $6,300/oz by end‑2026 JPM’s commodities team sees central‑bank and investor demand driving prices to $6,300; they estimate ~800t of central‑bank buying in 2026. 2026-02-02 Reuters factbox via Investing.com (Feb 2, 2026). (investing.com)
Bank of America Bullish $6,000/oz (12‑month view; “spring 2026”) BofA’s metals research flagged tightening supply, strong diversification demand, and policy uncertainty as drivers for a move toward $6,000. 2026-01-23 Kitco News report (Jan 23, 2026), as carried by Republic of Mining. (republicofmining.com)
Citigroup Neutral to positive near term; risks fade later in 2026 $5,000/oz (0–3 month target as of mid‑Jan 2026) Citi said overlapping geopolitical/economic risks support allocations now, but expects about half of those risks to fade later in 2026. 2026-01-30 Reuters wire via Kitco (Jan 30, 2026). (kitco.com)
UBS Bullish $6,200/oz (Jun & Sep 2026); $5,900/oz (Dec 2026) UBS CIO’s March update shows end‑period targets of $6,200 for mid‑2026 and $5,900 by year‑end, stressing the macro/policy backdrop as key. 2026-03-23 UBS CIO View: Gold (Mar 23, 2026). (ubs.com)
HSBC Positive H1; cautious H2 Peak to ~$5,000 in H1 2026; 2026 average ~$4,587; end‑2026 ~$4,450; range $3,950–$5,050 HSBC forecast a powerful H1 rally toward $5,000 with a potential correction later in 2026 as risk premia fade; detailed averages and ranges published in January. 2026-01-08 Reuters: HSBC sees ~$5,000 in H1’26; trims 2026 avg to ~$4,587; end‑year ~$4,450 (Jan 8, 2026). (archive.ph)
Deutsche Bank Bullish $6,000/oz in 2026 (reiterated late Jan) DB reiterated a 2026 forecast of ~$6,000/oz, citing sustained investor demand; CIO materials also discuss the rally and positioning dynamics. 2026-01-26 Reuters factbox summary (Jan 26, 2026) and DB CIO note (Feb 4, 2026). (investing.com)

Risk Considerations - Higher‑for‑longer real yields or a stronger USD would pressure gold and gold ETFs. (hsbc.com.my) - Rapid de‑escalation of geopolitical risks could remove part of the risk premium embedded in prices (Citi). (kitco.com) - Central‑bank buying slows materially versus 2022–2024 peaks (HSBC base case), reducing structural support. (lbma.org.uk) - Positioning/liquidity shocks (e.g., margin hikes) can trigger sharp drawdowns even in bull markets. (investing.com) - If rate‑cut timelines are pushed out further, near‑term downside risk rises (MS/HSBC). (morganstanley.com)

Position with a Buy bias in physically backed gold ETFs (GLD/IAU/BAR) on pullbacks; expect volatility but a constructive path into late‑2026 as risk premia, central‑bank demand and prospective policy easing underpin prices. Monitor real yields/USD and any durable easing in geopolitical risk as key challenge points. (morganstanley.com)


Stock Ratings — Selected Big-Cap Tech: Street Targets and Ratings (as of May 8, 2026)

Notes: Entries reflect the latest items we could find from each named institution for each ticker. Primary data comes from MarketBeat’s per‑ticker analyst-history pages (AAPL, MSFT, GOOGL, AMZN, NVDA, META, TSLA, AVGO, TSM), supplemented where needed by recent Investing.com posts and, for one JPMorgan NVDA item, StockAnalysis’ analyst tracker. Where a firm’s latest action didn’t disclose a target, the target is null. Consensus target/rating are computed only from the six requested institutions’ most recent entries with available data. Key sources include MarketBeat pages for AAPL, MSFT, GOOGL, AMZN, NVDA, META, TSLA, AVGO, and TSM, plus Investing.com coverage and StockAnalysis’ Harlan Sur page for NVDA.

AAPL - Apple Inc.

Coverage skewed Buy/Overweight across all six; most recent targets cluster in the low-to-mid $300s; consensus ~mid‑$320s.

Institution Rating Target Price Last Update Notes Source
Goldman Sachs Buy 340 - Raised to $340 while maintaining Buy (recent report). https://www.investing.com/news/analyst-ratings/goldman-sachs-raises-apple-stock-price-target-to-340-on-demand-93CH-4652003
Morgan Stanley Overweight 330 2026-05-01 Reiterated Overweight; target lift $315→$330. https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/
JP Morgan Overweight 325 2026-01-30 Boost target $315→$325; Overweight. https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/
Bank of America Buy 325 2026-03-12 Raised $320→$325; Buy. https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/
Citigroup Buy - 2026-04-17 Reiterated Buy; latest item didn’t show a target. https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/
Wells Fargo Overweight 310 2026-05-01 Reiterated Overweight; target lift $300→$310. https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/

Consensus View - Rating: Buy, Target Price: 326 - Average of 5 available targets (GS/MS/JPM/BAC/WFC).

MSFT - Microsoft Corp.

Banks remain constructive; multiple target trims post‑April but still Buy/Overweight; consensus ~mid‑$570s on available targets.

Institution Rating Target Price Last Update Notes Source
Goldman Sachs Buy - 2026-04-30 Reiterated Buy; target not shown in latest item. https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/
Morgan Stanley Overweight - 2026-01-29 Reiterated Overweight; no target printed in item. https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/
JP Morgan Overweight 550 2025-07-31 Lowered $575→$550; Overweight (still within 12 months). https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/
Bank of America Buy 500 2026-03-09 Initiated Buy with $500 PT. https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/
Citigroup Buy 620 2026-04-30 Raised $600→$620; Buy. https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/
Wells Fargo Overweight 625 2026-04-30 Raised $615→$625; Overweight. https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/

Consensus View - Rating: Buy, Target Price: 574 - Average across BAC/JPM/C/WFC targets with data.

GOOGL - Alphabet Inc.

Uniformly positive with broad target raises on Apr 30; one earlier WFC cut in Feb; consensus just above $410 on bank set.

Institution Rating Target Price Last Update Notes Source
Goldman Sachs Buy 450 2026-04-30 Raised $400→$450; Buy. https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/
Morgan Stanley Overweight 375 2026-04-30 Raised $330→$375; Overweight. https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/
JP Morgan Buy - 2026-05-04 Reiterated Buy; target not shown in that item. https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/
Bank of America Buy 430 2026-04-30 Raised $370→$430; Buy. https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/
Citigroup Buy 445 2026-05-04 Raised $380→$445; Buy. https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/
Wells Fargo Overweight 361 2026-02-23 Cut $397→$361; Overweight. https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/

Consensus View - Rating: Buy, Target Price: 412.2 - Average of GS/MS/BAC/C/WFC targets.

AMZN - Amazon.com Inc.

All six raised or reiterated Buys around April 30 on AI/AWS updates; bank-set consensus a bit above $320.

Institution Rating Target Price Last Update Notes Source
Goldman Sachs Buy 325 2026-04-30 Raised $275→$325; Buy. https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/
Morgan Stanley Overweight 330 2026-04-30 Raised $300→$330; Overweight. https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/
JP Morgan Overweight 330 2026-04-30 Raised $280→$330; Overweight. https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/
Bank of America Buy 310 2026-04-30 Raised $298→$310; Buy. https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/
Citigroup Buy 325 2026-04-30 Raised $285→$325; Buy. https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/
Wells Fargo Overweight 313 2026-04-30 Raised $307→$313; Overweight. https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/

Consensus View - Rating: Buy, Target Price: 322.2 - Average of all six banks’ latest targets.

NVDA - NVIDIA Corp.

All six stay constructive; targets span $250–$275 from the money‑center banks; consensus mid‑$260s.

Institution Rating Target Price Last Update Notes Source
Goldman Sachs Buy 250 2026-05-07 Reiterated Buy and $250 PT. https://www.investing.com/equities/nvidia-corp-consensus-estimates
Morgan Stanley Overweight 260 2026-03-17 Reiterated Overweight; $260 PT. https://uk.investing.com/news/analyst-ratings/morgan-stanley-reiterates-overweight-on-nvidia-stock-260-target-93CH-4562719
JP Morgan Overweight 265 2026-03-17 Harlan Sur reiterated Overweight; PT to $265. https://uk.investing.com/news/analyst-ratings/jpmorgan-reiterates-nvidia-stock-rating-on-expanded-demand-visibility-93CH-4563214
Bank of America Buy 275 2026-01-06 Reiterated Buy; $275 PT. https://www.investing.com/news/analyst-ratings/bofa-securities-reaffirms-nvidia-stock-buy-rating-with-275-price-target-93CH-4431532
Citigroup Buy 270 - Reiterated Buy; $270 PT (CES wrap). https://uk.investing.com/news/analyst-ratings/citi-reiterates-buy-rating-on-nvidia-stock-maintains-270-price-target-93CH-4442594
Wells Fargo Overweight 265 - Raised PT to $265; Overweight. https://es.investing.com/news/analyst-ratings/wells-fargo-eleva-el-precio-objetivo-de-las-acciones-de-nvidia-a-265-dolares-por-las-perspectivas-de-crecimiento-de-la-ia-93CH-3396621

Consensus View - Rating: Buy, Target Price: 264.2 - Simple average of the six bank PTs.

META - Meta Platforms Inc.

Post‑Q1 capex update sparked target trims but bank stance remains Buy/Overweight; available targets cluster ~high‑$700s to low‑$800s.

Institution Rating Target Price Last Update Notes Source
Goldman Sachs Buy - 2025-08-05 Most recent MB item shows a Buy reiteration; no PT shown there. https://www.marketbeat.com/stocks/NASDAQ/META/forecast/
Morgan Stanley Overweight 775 2026-03-27 Lowered $825→$775; Overweight. https://www.marketbeat.com/stocks/NASDAQ/META/forecast/
JP Morgan - - - Coverage present on MB page; most recent detailed line not shown in capture. https://www.marketbeat.com/stocks/NASDAQ/META/forecast/
Bank of America Buy 820 2026-04-10 Lowered $885→$820; Buy. https://www.marketbeat.com/stocks/NASDAQ/META/forecast/
Citigroup Outperform - 2026-01-29 Reiterated Outperform; target not shown in that line. https://www.marketbeat.com/stocks/NASDAQ/META/forecast/
Wells Fargo Overweight 770 2026-04-30 Raised $765→$770; Overweight. https://www.marketbeat.com/stocks/NASDAQ/META/forecast/

Consensus View - Rating: Buy, Target Price: 788.3 - Average across MS/BAC/WFC targets with data.

TSLA - Tesla Inc.

Mixed across banks; limited fresh color from some of the six since January; available targets vary widely.

Institution Rating Target Price Last Update Notes Source
Goldman Sachs - - - Coverage present; latest detailed line not captured here. https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/
Morgan Stanley - - - Coverage present; latest detailed line not captured here. https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/
JP Morgan - - - Coverage present; latest detailed line not captured here. https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/
Bank of America - - - Coverage present; line not captured in this pass. https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/
Citigroup Neutral 258 - Lowered $274→$258; Neutral. https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/
Wells Fargo Underweight 125 2026-01-06 Cut $130→$125; Underweight. https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/

Consensus View - Rating: Hold, Target Price: 191.5 - Computed on partial data (C and WFC only). Treat as provisional.

AVGO - AVGO Corp.

Sparse recent bank updates in public summaries; GS reiterated Buy late‑2025 with a $450 PT.

Institution Rating Target Price Last Update Notes Source
Goldman Sachs Buy 450 2025-12-15 Reiterated Buy; $450 PT. https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/
Morgan Stanley - - - Coverage present; latest detailed line not captured here. https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/
JP Morgan - - - Coverage present; latest detailed line not captured here. https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/
Bank of America - - - Coverage present; detailed item not captured here. https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/
Citigroup - - - Coverage present; detailed item not captured. https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/
Wells Fargo - - - Coverage present; detailed item not captured. https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/

Consensus View - Rating: Buy, Target Price: 450 - Consensus reflects only GS entry available here; more bank details can be added on request.

TSM - TSM Corp.

Limited public detail in our pass; Citi most recently reiterated Buy.

Institution Rating Target Price Last Update Notes Source
Goldman Sachs - - - Coverage likely; latest public item not captured here. https://www.marketbeat.com/stocks/NYSE/TSM/forecast/
Morgan Stanley - - - Coverage likely; latest public item not captured here. https://www.marketbeat.com/stocks/NYSE/TSM/forecast/
JP Morgan - - - Coverage likely; latest public item not captured here. https://www.marketbeat.com/stocks/NYSE/TSM/forecast/
Bank of America - - - Coverage likely; latest public item not captured here. https://www.marketbeat.com/stocks/NYSE/TSM/forecast/
Citigroup Buy - 2026-01-05 Reiterated Buy; target not shown on MB line. https://www.marketbeat.com/stocks/NYSE/TSM/forecast/
Wells Fargo - - - Coverage likely; latest public item not captured here. https://www.marketbeat.com/stocks/NYSE/TSM/forecast/

Consensus View - Rating: Buy - Consensus reflects Citi’s Buy only; fuller bank set needed for target.

Highlights

  • All six banks remain Buy/Overweight on AMZN; average target ~$322 across this cohort. (MarketBeat AMZN page, Apr 30 batch.)
  • For NVDA, GS/MS/JPM/BAC/C/WFC cluster between $250–$275; average ~$264. (Investing.com and StockAnalysis items cited in-line above.)
  • AAPL shows five of six banks with explicit targets; average ~$326; Citi most recent item was a Buy reiteration without a stated PT. (MarketBeat AAPL page.)

Gaps: For TSLA, AVGO, and TSM, several institutions’ most recent public summaries did not include clear price targets in sources we can cite directly. I can fill those in next by pulling each bank’s latest note as reported in reliable wires (Reuters/Bloomberg) or additional aggregator entries. If you want, I’ll prioritize any symbols first.


IPO Calendar

Timeframe: May 8, 2026 to June 8, 2026 (US equity markets)

The next 30 days are anchored by several large, infrastructure‑oriented IPOs—an AI‑hardware leader (Cerebras), a data‑center REIT from Blackstone, and geothermal power developer Fervo—alongside a mid‑cap Permian land company (EagleRock) and a commercial‑stage medtech (Mobia). The calendar is front‑loaded around the week of May 13–14, and terms remain subject to change as books build. Recent pricing momentum (e.g., HawkEye 360, Suja Life, Odyssey Therapeutics) suggests investors will focus on profitability paths, customer concentration, and power/infrastructure exposure. (investing.com)

Cerebras Systems Inc. (CBRS)

  • Expected listing date: 2026-05-14
  • Price range: $115–$125 per share (roadshow launched May 4, 2026)
  • Shares offered: 28,000,000 Class A shares offered; 30‑day underwriters’ option up to 4,200,000 additional shares
  • Exchange: Nasdaq Global Select Market
  • Lead underwriters: Morgan Stanley & Co. LLC, Citigroup Global Markets Inc., Barclays Capital Inc., UBS Investment Bank
  • Business summary: US‑based AI semiconductor and systems company building wafer‑scale processors (WSE‑3) and rack‑scale AI infrastructure for training and inference workloads.
  • Notes: Issuer has applied to list under “CBRS”; final pricing and allocations TBD based on bookbuilding and market conditions. Additional bookrunners/co‑managers per company press: Mizuho, TD Cowen; co‑managers include Needham, Craig‑Hallum, Wedbush, Rosenblatt, Academy Securities, Crédit Agricole CIB, MUFG, and First Citizens Capital Securities.
  • Sources: Cerebras press release with terms/underwriters. (cerebras.ai), SEC filing index and exhibits (S‑1/A; EX‑1.1 underwriters). (sec.gov), Reuters coverage of price range/roadshow (via Investing.com). (investing.com)

Fervo Energy Company (FRVO)

  • Expected listing date: 2026-05-13
  • Price range: $21–$24 per share
  • Shares offered: 55,555,555 Class A shares; 30‑day underwriters’ option (size per filing)
  • Exchange: Nasdaq
  • Lead underwriters: J.P. Morgan Securities LLC, BofA Securities, Inc., RBC Capital Markets, LLC, Barclays Capital Inc.
  • Business summary: US geothermal developer focused on enhanced geothermal systems (EGS) to supply 24/7, low‑carbon baseload power—positioned to serve rising data‑center and grid needs.
  • Notes: Terms and date based on the latest S‑1/A and deal updates; additional bookrunning managers listed include Baird, BBVA, Guggenheim Securities, MUFG, Société Générale, William Blair, Piper Sandler, and Wolfe | Nomura Alliance.
  • Sources: SEC S‑1/A filing index and EX‑1.1 (underwriting reps). (sec.gov), Bloomberg summary of terms (55.56M shares at $21–$24). (bloomberg.com), Company/press notice of public filing and Nasdaq symbol. (globenewswire.com), Deal terms/underwriters as reflected on prospectus cover (S‑1/A). (sec.gov)

Blackstone Digital Infrastructure Trust Inc. (BXDC)

  • Expected listing date: 2026-05-14
  • Price range: Fixed at $20.00 per share (per current filed terms)
  • Shares offered: 87,500,000 primary shares; 30‑day option up to 12,995,000 shares; includes 725,987 “bonus shares” (with up to 129,950 additional bonus shares if option exercised)
  • Exchange: New York Stock Exchange (NYSE)
  • Lead underwriters: Goldman Sachs & Co. LLC (lead; additional underwriters not fully disclosed in press materials)
  • Business summary: Newly organized REIT intended to acquire and own stabilized, newly constructed data centers—targeting AI/hyperscale demand with long‑term, investment‑grade tenants.
  • Notes: S‑11/A shows fixed‑price structure with bonus‑share feature; full underwriter roster may be finalized at pricing. Listing/timing subject to SEC effectiveness and market conditions.
  • Sources: Blackstone press release on public S‑11 filing and intended ticker. (blackstone.com), SEC S‑11/A counsel exhibit detailing share counts/bonus‑share mechanics. (sec.gov), Reuters/Bloomberg coverage of $1.75B target and $20 price. (investing.com), IPO calendar detail. (ipox.com)

EagleRock Land, LLC (EROK)

  • Expected listing date: 2026-05-14
  • Price range: $17–$20 per Class A share
  • Shares offered: 17,300,000 Class A shares (representing LLC interests)
  • Exchange: New York Stock Exchange (issuer has also referenced ‘NYSE Texas’ in certain materials)
  • Lead underwriters: Goldman Sachs & Co. LLC (lead manager per industry tracker)
  • Business summary: Permian Basin land management and royalty company that owns/controls surface acreage and collects royalties and fees tied to oil & gas activity and related infrastructure.
  • Notes: Issuer materials mention applications to list on NYSE and ‘NYSE Texas’; mechanics and final venue disclosures may be updated at pricing. Date/size subject to change.
  • Sources: Business Wire press release (launch of IPO; range and 17.3M shares). (morningstar.com), Investing.com/Reuters deal term summaries. (investing.com), IPO Boutique/CCH trackers indicating lead manager and timetable. (ipoboutique.com)

Mobia Medical, Inc. (MOBI)

  • Expected listing date: 2026-05-08
  • Price range: $14–$16 per share
  • Shares offered: 10,000,000 shares; 30‑day underwriters’ option (per prospectus)
  • Exchange: Nasdaq Global Select Market
  • Lead underwriters: BofA Securities, Inc., J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC
  • Business summary: Commercial‑stage medtech focused on stroke motor‑recovery; its Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System is FDA‑approved for chronic ischemic stroke survivors with upper‑extremity impairment.
  • Notes: Company formerly MicroTransponder; name changed to Mobia Medical on Feb 24, 2026. Co‑managers include BTIG and Wolfe | Nomura Alliance per filing. Pricing expected the week of May 6–10, 2026, subject to market conditions.
  • Sources: SEC S‑1/A (cover: exchange/ticker; underwriting syndicate). (sec.gov), Renaissance/press coverage of set terms ($14–$16; 10M shares). (renaissancecapital.com), Company name‑change press release. (globenewswire.com)

IPO timing, pricing, share counts, exchanges and syndicate lineups may change or be withdrawn before pricing; always confirm the issuer’s latest SEC filings and any official press releases ahead of orders. Some items above reflect preliminary terms in S‑1/S‑11 filings or company press and may update at pricing. Where underwriter rosters are partially disclosed in public materials (e.g., BXDC, EROK), we’ve listed the confirmed lead(s) and noted that additional banks may be named at pricing.


Sources

  • Stock Ratings: https://es.investing.com/news/analyst-ratings/wells-fargo-eleva-el-precio-objetivo-de-las-acciones-de-nvidia-a-265-dolares-por-las-perspectivas-de-crecimiento-de-la-ia-93CH-3396621, https://uk.investing.com/news/analyst-ratings/citi-reiterates-buy-rating-on-nvidia-stock-maintains-270-price-target-93CH-4442594, https://uk.investing.com/news/analyst-ratings/jpmorgan-reiterates-nvidia-stock-rating-on-expanded-demand-visibility-93CH-4563214, https://uk.investing.com/news/analyst-ratings/morgan-stanley-reiterates-overweight-on-nvidia-stock-260-target-93CH-4562719, https://www.investing.com/equities/nvidia-corp-consensus-estimates, https://www.investing.com/news/analyst-ratings/bofa-securities-reaffirms-nvidia-stock-buy-rating-with-275-price-target-93CH-4431532, https://www.investing.com/news/analyst-ratings/goldman-sachs-raises-apple-stock-price-target-to-340-on-demand-93CH-4652003, https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/, https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/, https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/, https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/, https://www.marketbeat.com/stocks/NASDAQ/META/forecast/, https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/, https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/, https://www.marketbeat.com/stocks/NYSE/TSM/forecast/
  • IPO Calendar: https://www.blackstone.com/news/press/blackstone-digital-infrastructure-trust-announces-public-filing-of-registration-statement-with-the-sec/?utm_source=openai, https://www.bloomberg.com/news/articles/2026-05-04/geothermal-energy-developer-fervo-seeks-1-33-billion-in-us-ipo?utm_source=openai, https://www.cerebras.ai/press-release/cerebras-systems-announces-launch-of-initial-public-offering, https://www.globenewswire.com/news-release/2026/02/24/3243463/0/en/MicroTransponder-Announces-Corporate-Name-Change-to-Mobia-Medical.html?utm_source=openai, https://www.globenewswire.com/news-release/2026/04/17/3276524/0/en/Fervo-Energy-Publicly-Announces-Filing-of-Registration-Statement-for-Proposed-Initial-Public-Offering.html?utm_source=openai, https://www.investing.com/ipo-calendar/, https://www.investing.com/news/stock-market-news/ai-chipmaker-cerebras-targets-115125-share-price-in-us-ipo-source-says-4655096?utm_source=openai, https://www.investing.com/news/stock-market-news/blackstone-vehicle-aims-to-raise-over-17-billion-in-us-ipo-to-fund-data-center-bet-4656127?utm_source=openai, https://www.investing.com/news/stock-market-news/eaglerock-land-files-for-ipo-offering-173-million-shares-432SI-4655637?utm_source=openai, https://www.ipoboutique.com/cgi/info/EagleRockLand-EROK?utm_source=openai, https://www.ipox.com/ipo-calendar/blackstone-digital-infrastructure-trust?utm_source=openai, https://www.morningstar.com/news/business-wire/20260503421074/eaglerock-announces-launch-of-initial-public-offering?utm_source=openai, https://www.renaissancecapital.com/IPO-Center/News/118736/Nerve-stimulation-device-maker-Mobia-Medical-sets-terms-for-%24150-million-IP?utm_source=openai, https://www.sec.gov/Archives/edgar/data/1489993/000162828026027560/mobiamedical-sx1a.htm, https://www.sec.gov/Archives/edgar/data/1853868/000162828026029515/0001628280-26-029515-index.htm, https://www.sec.gov/Archives/edgar/data/1853868/000162828026029515/fervoenergy-sx1a.htm?utm_source=openai, https://www.sec.gov/Archives/edgar/data/2021728/000162828026029503/0001628280-26-029503-index.htm, https://www.sec.gov/Archives/edgar/data/2100161/000119312526202510/d52761dex51.htm?utm_source=openai

Disclaimer

This research report is for informational purposes only and does not constitute investment advice. All information is sourced from publicly available data and should be verified independently. Past performance does not guarantee future results.

Generated on: 2026-05-08 at 11:41 UTC
Source: Alpha Signal Monitor - Automated Research System
Contact: For questions about this report, please contact your Alpha Signal Monitor administrator.


Powered by Alpha Signal Monitor | Market Intelligence Through AI

Don't miss what's next. Subscribe to Alpha:
Powered by Buttondown, the easiest way to start and grow your newsletter.